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Summary
Purpose: Aim of this study was to evaluate the efficacy and tolerability of the
antiepileptic drug topiramate (TPM) in a sample of patients with nocturnal frontal
lobe epilepsy (NFLE).
Methods: A 24 patients with video-polysomnographically confirmed NFLE received
topiramate as single or add-on therapy. They all completed diaries concerning the
seizures frequency and complexity and underwent to periodic follow-up visits. We
classified the patients as: seizure-free, responders or non-responders.
Results: 15 M; 9 F; mean age 29.3  10.4 years. The video-polysomnographic record-
ings showed a wide spectrum of seizures, ranging from repeated stereotypic brief
motor attacks to prolonged attacks, with complex and bizarre behaviour; the
recorded episodes occurred during non-REM sleep, both stage 2 and stage 3—4.
The EEG during wakefulness was normal in all the patients, while seven of them
showed epileptiform abnormalities during polysomnography. TPMwas administered as
single or add-on therapy from 50 to 300 mg daily at bedtime. The follow-up duration
ranged from 6 months to 6 years. The patients were classified as: seizure-free = 6
(25%); responders (reduction of at least 50% of seizures) = 15 (62.5%); non-respon-
ders = 3 (12.5%). The adverse events were: weight loss (6 pts, 25%); paresthesias (3
pts, 12.5%); speech dysfunction (2 pts, 8.3%). All the adverse events disappeared
within 3 months.
Conclusions: In our experience, TPM seems to be effective in about 90% of patients
with NFLE. Few of them experienced transitory adverse events. TPM could be included
in the options for patients with this form of epilepsy.
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In the last years, a distinct form of clear-cut seizures
arising from epileptic foci located within the frontal. Published by Elsevier Ltd. All rights reserved.
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emerging almost exclusively from sleep has been
described with the term of nocturnal frontal lobe
epilepsy (NFLE).1—4 Seizures are characterized by a
wide spectrum of clinical features: assumption of
postures, rhythmic and repetitive movements of
arms and legs, rapid uncoordinated movements,
with dystonic or dyskinetic components, complex
motor activities (deambulation, wandering, pelvic
thrusting), sudden elevation of the trunk and head
associated with expression of fear and vocalization.
Provini et al.4 in a series of 100 consecutive
patients with NFLE emphasized the usefulness of
a clinical distinction of motor manifestations into
three subgroups–—(a) paroxysmal arousals: brief
(<20 s) episodes characterized by sudden eye open-
ing, head raising or sitting up in bed, often with a
frightened expression and sometimes vocalization;
(b) nocturnal paroxysmal dystonia: episodes of
intermediate duration (20 s—2 min) characterized
by wide, often ballistic movements, dystonic pos-
turing or choreoathetoid movements of head, trunk
and limbs and vocalization3; episodic nocturnal
wandering: episodes of longest duration (1—3 min)
with stereotyped, paroxysmal ambulation, accom-
panied by screaming and bizarre, dystonic move-
ments. All three types of seizures frequently occur
in the same patients.
Ictal and interictal standard EEG are often usually
normal or not interpretable because of the presence
of muscular artefacts.3,4 Only sphenoidal and intra-
cerebral EEG recordings can help to identify ictal
and/or interictal discharges.1,5 In some cases, the
electro-clinical analysis of the ictal episodes suggests
an extra-frontal origin of the attacks. In the litera-
ture, and also in our sample, with the term of NFLE
are likely included some patients with complex noc-
turnal motor automatisms of extra-frontal origin.6
In about two-third of patients carbamazepine
(CBZ) is reported to greatly reduce nocturnal sei-
zures in frequency and complexity.1,4,7 In this kind of
epilepsy, seizures are almost exclusively during
sleep and the patients are often unaware of the
presence, complexity and frequency of attacks.
Probably due to this difficulty in monitoring the
seizures frequency, extensive data about the phar-
macological treatment of NFLE are still lacking.
Aim of this study is to evaluate the efficacy and
tolerability of the antiepileptic drug topiramate
(TPM) in a sample of patients with NFLE.Patients and methods
Twenty-four consecutive patients admitted to our
Sleep Disorders Center from 1998 to 2003 for noc-turnal paroxysmal episodes suggestive of NFLE
underwent: neurological examination; detailed
sleep interview with parents or bed partner; elec-
troencephalographic studies during wakefulness;
cerebral magnetic resonance imaging; full night
video-polysomnography (after an adaptation night
to the laboratory) including EEG monitoring (stan-
dard bipolar leads positioned according to the
International 10—20 System), electrooculogram,
submental electromyography, EKG and, in most
cases, electromyography of arms and legs and
abdominal and/or thoracic respiratory movements.
We analysed all the video-polysomnographic
recordings and selected all the pathological motor
events. We examined the EEG tracing and compared
the seizures semeiology with the EEG patterns.
Sleep was scored according to international cri-
teria.8 According to literature data,4 the diagnosis
of NFLE was straightforward when patients dis-
played one or more motor episodes, of any kind
of intensity and duration, associated with clear-cut
ictal epileptiform activity during polysomnography.
When ictal EEG was uninformative, we required the
recording of two or more seizures with a stereotypic
motor pattern.
In order to record and describe the seizure pat-
tern, the antiepileptic therapy was gradually
reduced by 50% within 1 week before polysomno-
graphy, in three patients already under treatment
(CBZ 800 mg/d in one case and 1000 mg/d in the
other two cases). All these patients were non-
responders to CBZ treatment. None of our 24
patients was taking psychoactive medications in
the month before the visit. They all received TPM
as single or add-on therapy. The initial dose of TPM
was of 25 mg/d at 9 p.m., and it was increased every
7 days by 25 mg/d until a satisfactory control of
symptoms was reported or until side effects began
to appear.
They all completed, with the aid of parents or the
bed partner, detailed diaries concerning the sei-
zures frequency and complexity. All the patients
underwent periodic (every 6 months) follow-up vis-
its (with the presence of parents or bed partner).
Eight of them underwent a second nocturnal video-
polysomnography. We classified the patients as:
seizure-free (disappearance of seizures since start-
ing TPM); responders (reduction of at least 50% of
seizures); non-responders (reduction of less than
50% of seizures).Results
The patients were 15 males and 9 females, with a
mean age of 29.3  10.4 years; the seizures began in
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Table 1
Age/sex TPM daily dose Seizures I Seizures II EEG I EEG II Seizures log Seizures PSG
M 36 100 5 PA 2 PA — — SF R
M 26 200 2 NPD — — — SF SF
M 27 100 4 PA — P (R; L) P (R; L) SF SF
M 28 200 5 PA 1 PA — — R R
M 25 150 5 NPD — — — SF SF
F 24 100 2 NPD — T (L) T (L) R SF
F 33 150 3 PA — FT (L) FT (L) NR SF
M 28 200 3 PA — — — R SF
Seizures I: seizures during the diagnostic polysomnography; Seizures II: seizures during the second polysomnography; EEG I: EEG
abnormalities during the diagnostic polysomnography; EEG II: EEG abnormalities during the second polysomnography; P: parietal; T:
temporal; FT: fronto-temporal; R: right; L: left; Seizures log: subjective report of seizures during the last month; Seizures PSG:
seizures during the second polysomnography; SF: seizure free; R: responders; NR: non-responders.childhood (the age at onset ranged from 4 to 40
years; mean 14.6  10.5 years) and persisted
throughout adult life. Nine of them reported similar
nocturnal seizures in other family relatives, with a
pedigree consistent with an autosomal dominant
pattern of inheritance (i.e. ADNFLE). Three patients
presented daytime focal seizures with possible sec-
ondary generalization.
The video-polysomnographic recordings showed a
wide spectrum of seizures, ranging from repeated
stereotypic brief motor attacks (paroxysmal arou-
sals) to prolonged attacks, with complex and bizarre
behaviour, assumption of abnormal posture, dys-
tonic bipedal and/or bimanualmovements, shouting
and/or unintelligible mumbling (nocturnal paroxys-
mal dystonia and nocturnal wandering).
The recorded episodes occurred during non-rapid
eye movements sleep, both stage 2 and stage 3—4.
The EEG during wakefulness was normal in all the
patients, while seven of them showed epileptiform
abnormalities during polysomnography. Only one
patient showed neuroradiological abnormalities
(focal frontal pachigyria).
At the first visit, three patients were treated by
CBZ: in these cases, TPMwas administered as add-on
therapy. Twenty-one patients were drug-free and
have never been treated before by antiepileptic
drugs: in these cases, TPM was administered as
monotherapy, ranging from 50 to 300 mg daily at
bedtime (mean 132.3  55.4 mg). The follow-up
duration ranged from 6 months to 6 years (mean
2.3  1.4 years).
On the basis of the analysis of the seizure logs,
the patients were classified as: seizure-free = 6
(25%); responders = 15 (62.5%); non-responders = 3
(12.5%). The response to TPM was assessed by com-
paring the absolute number of attacks over the 3
months before starting TPM treatment to the 1 of
the 3 months which preceded the clinical follow-up.
In the 21 responders patients (including 6 seizure-free patients), the mean dosage of TPM was
102.2  24.4 mg, while in the 3 non-responders it
was 233.0 (range 150—300).
We recorded the following adverse events:
weight loss (mean 3.8  2.3 kg) in 6 pts (25%) at
the first 6 months clinical follow-up; paresthesias in
3 pts (12.5%) and speech dysfunction in phonematic
verbal fluency in 2 pts (8.3%). All the adverse events
disappeared spontaneously within 3 months. No
patients reduced or withdrew TPM due to adverse
events.
We compared the data of the seizures logs
with the polysomnographical data of the second
night for the eight patients available: in six cases
(75%) there was an agreement between the data
(Table 1).Discussion
NFLE has been described as sporadic and familial
form. Autosomal dominant NFLE (ADNFLE) was first
described by Scheffer et al.9 in 1994: the authors
collected six families with 39 affected individuals in
Australia, United Kingdom and Canada and were
able to demonstrate monogenic inheritance with
an autosomal dominant transmission pattern. After-
wards further families, most of them of Caucasian
origin, have been described.7,10,11
Up to 40% of patients affected by NFLE reported
parasomniac behaviour (sleep-talking; sleep-walk-
ing; sleep terrors; primary enuresis; bruxism) in at
least one of their first degree relatives. The coex-
istence between parasomnia and NFLE, together
with the typical NFLE clinical and EEG profile, could
generate diagnostic difficulties in differentiating
the two conditions.
The EEG studies in NFLE during wakefulness
(and often also during sleep) are usually normal.
Moreover, the patients are often unaware of the
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these reasons, there are relatively few data about
the clinical, video-polysomnographical and, parti-
cularly, pharmacological profiles of NFLE.
CBZ is reported to greatly reduce nocturnal sei-
zures in frequency and complexity in about two-
third of patients.1,4,7 Varadkar et al.12 reported
three members of a family with ADNFLE that
responded to acetazolamide (ACZ) as add-on ther-
apy to CBZ. As ADNFLE is suspected to be a channe-
lopathy, the authors hypothesized that ACZ may be
exerting its therapeutic effect through this action,
rather than by potentiating CBZ.
The antiepileptic drug topiramate is known to be
effective in new-onset partial epilepsies13 aswell as
in refractory partial and generalized epilepsies.14
The most common adverse events include somno-
lence, anorexia, weigh loss, paresthesias and psy-
chomotor slowing. In our case series, topiramate
seems to be effective in NFLE: about 90% of patients
had a good response to a low dose of the drug.
Probably due to the low dose (mean 132 mg at
bedtime), few of them experienced (transitory)
adverse events. The efficacy of TPM in new-onset
partial epilepsies and refractory partial and gen-
eralized epilepsies is sustained by several class I
studies (prospective, randomized, controlled clin-
ical trial with masked outcome assessment, in a
representative population).13,14 There are insuffi-
cient data to make recomendation for the syn-
dromes individually, including NFLE. According to
the results of genetic investigations, mutations in
alpha 4 beta 2 subunit of the nicotinic acetylcholine
receptor could play a role in the NFLE pathogenesis.
Since among the proposed sites of TPM action
(voltage-activated Na+ channels; GABAA receptor;
glutamate receptor; Ca2+ channel; carbonic anhy-
drase) the acetylcholine receptor is not included, a
clear molecular explanation for these results is
actually not available and should be further inves-
tigated.15,16
On the basis of the present case series (class IV
study) we cannot make specific recomendation for
NFLE, but we could include topiramate in the
options for patients with NFLE. Considering the
possible extra-frontal origin of complex nocturnal
motor seizures,5,6 the effectiveness of TPM could be
widen to patients with sleep-related epileptic
attacks with complex motor behaviours (i.e. focal
epilepsy with sleep-related seizures).References
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